EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Development of the Japanese version of the 30‐item Mystical Experience Questionnaire

Kengo Yonezawa, Hideaki Tani, Shinichiro Nakajima, Hiroyuki Uchida iD

Neuropsychopharmacology Reports · 2024

DOI: 10.1002/npr2.12377 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Neuropsychopharmacology Reports, 2024. Verfasst von Kengo Yonezawa und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neuropsychiatry, Keio University School of Medicine, Tokyo, Japan. Hauptthemen laut MEDLINE: Hallucinogens, Mental Disorders. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Japan Agency for Medical Research and Development.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Psychedelics have garnered increased attention as potential therapeutic options for various mental illnesses. Previous studies reported that psychedelics cause psychoactive effects through mystical experiences induced by these substances, including an altered state of consciousness. While this phenomenon is commonly assessed by the Mystical Experiences Questionnaire (MEQ30), a Japanese version of the MEQ30 has not been available. The aim of this study was to develop the Japanese version of the MEQ30.

Methods

We adhered to the “Principles of Good Practice for the Translation and Cultural Adaptation Process for Patient‐Reported Outcomes (PRO) Measures: Report of the ISPOR Task Force for Translation and Cultural Adaptation” in our translation process. Two Japanese psychiatrists independently performed forward translations, from which a unified version was derived through reconciliation. This version was subsequently back‐translated into English and reviewed by the original authors for equivalency. The iterative revision process was carried out through ongoing discussions with the original authors until they approved the final back‐translated version.

Results

The final, approved back‐translated version of the MEQ30 is presented in the accompanying figure. Additionally, the authorized Japanese version of the MEQ30 is included in the Appendix A.

Conclusions

In this study, we successfully developed a Japanese version of the MEQ30. This scale will facilitate the assessment of mystical experiences associated with psychedelic‐assisted therapy among Japanese speakers. Further research is warranted to evaluate the reliability and validity of this newly translated scale.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HallucinogensMental DisordersHumansReproducibility of ResultsJapanSurveys and Questionnaires

Stichwörter der Autor:innen

Mystical Experiences Questionnairehumanpsychedelics

Substanzen

Hallucinogens

Autor:innen und Institutionen

  • Department of Neuropsychiatry, Keio University School of Medicine, Tokyo, Japan.

ORCID-Profile: Hiroyuki Uchida

Förderung

  • Japan Agency for Medical Research and Development

Zitieren

APA

Yonezawa, K., Tani, H., Nakajima, S., & Uchida, H. (2024). Development of the Japanese version of the 30‐item Mystical Experience Questionnaire. Neuropsychopharmacology Reports. https://doi.org/10.1002/npr2.12377

Vancouver

Yonezawa K, Tani H, Nakajima S, Uchida H. Development of the Japanese version of the 30‐item Mystical Experience Questionnaire. Neuropsychopharmacology Reports. 2024. doi:10.1002/npr2.12377

BibTeX
@article{Yonezawa2024,
  author = {Yonezawa, Kengo and Tani, Hideaki and Nakajima, Shinichiro and Uchida, Hiroyuki},
  title = {Development of the Japanese version of the 30‐item Mystical Experience Questionnaire},
  journal = {Neuropsychopharmacology Reports},
  year = {2024},
  doi = {10.1002/npr2.12377}
}
Kostenlos starten →